Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

United Therapeutics (UTHR) is strongly positioned for another earnings beat, building on a historical average positive surprise of 3.44% over its last two quarterly reports. This expectation is reinforced by a positive Zacks Earnings ESP of +8.31% and a Zacks Rank #3 (Hold), a combination that historically indicates a positive earnings surprise in nearly 70% of cases, suggesting a high probability for UTHR's upcoming results.

Analysis

United Therapeutics (UTHR) presents a compelling case for a potential earnings beat in its next quarterly report, primarily driven by forward-looking analyst sentiment rather than a clear historical precedent from the provided data. The key bullish indicator is the company's Zacks Earnings ESP (Expected Surprise Prediction) of +8.31%, which signifies that the most recent analyst estimates are trending higher than the consensus. According to the report's methodology, this positive ESP, when combined with the stock's Zacks Rank #3 (Hold), has historically yielded a positive earnings surprise nearly 70% of the time. However, the article's reference to historical performance contains a notable inconsistency; while it claims an average surprise of 3.44% for the past two quarters, the figures provided for the most recent quarter show a reported EPS of $6.29 against an expected $6.63, which constitutes a miss. This contradicts the article's stated 5.41% positive surprise for that period, suggesting the optimistic outlook is almost entirely predicated on the predictive power of the ESP metric and recent analyst revisions, rather than a consistent track record of recent beats.

Key Decisions for Investors

• Given the strong positive Earnings ESP of +8.31%, investors may consider the stock for a short-term tactical play ahead of the earnings release, anticipating a potential share price increase from an earnings beat.
• It is crucial to note the data inconsistency in the article's historical analysis, as the reported miss in the most recent quarter undermines claims of a consistent beat history; therefore, reliance on this factor should be minimized.
• For investors holding UTHR, the Zacks #3 'Hold' rank combined with the bullish ESP suggests maintaining the current position while preparing for volatility, as a positive surprise is statistically likely but not guaranteed by fundamentals presented.